Canaccord analyst Kingsley Crane initiated coverage of Infleqtion with a Buy rating and $22 price target, which offers 70% upside from current levels. The company's neutral atom approach offers "compelling scaling and error-correction flexibility," the analyst tells investors in a research note. Canaccord believes Infleqtion has "scarcity value" as the only pure-play neutral-atom listed U.S. company. It says the company's software and component businesses strengthen the platform and diversify exposure.
